Trade Aytu BioScience, Inc. - AYTU CFD

Trading Conditions

• Spread: 0.198
• Long position overnight feeLong position overnight feeMargin. Your investment$1,000.00Overnight feeCharges from full value of position-0.026179 %(-$1.05)Trade size with leverage ~ $5,000.00Short position overnight fee ~ $4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investment$1,000.00Overnight feeCharges from full value of position0.003957 %($0.16)Trade size with leverage ~ $5,000.00Short position overnight fee ~ $4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 0.01
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: $1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-$1.05)

• Margin. Your investment: $1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  ($0.16)

Key Stats

• Prev. Close: 2.786
• Open: 2.686
• 1-Year Change: 20.5%
• Day's Range: 2.686 - 2.746

Aytu BioScience, Inc. Company profile

About Aytu Biopharma Inc

Aytu Biopharma, Inc., formerly Aytu BioScience, Inc., is a specialty pharmaceutical company. The Company markets a portfolio of prescription products addressing primary care and pediatric markets. The Company's primary prescription products treat attention deficit hyperactivity disorder (ADHD) and other common pediatric conditions. It markets ADHD products Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets, Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets, and Adzenys-ER (amphetamine) extended-release oral suspension. The Company's other pediatric products include Karbinal ER (carbinoxamine maleate), an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines containing combinations of fluoride and vitamins in formulations for infants and children with fluoride deficiency.

Financial summary

BRIEF: For the six months ended 31 December 2021, Aytu Biopharma Inc revenues increased 57% to $45M. Net loss increased from $13.8M to $39.4M. Revenues reflect United States segment increase of 69% to $43.7M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.07 to -$1.53.

Equity composition

Common Stock no Par, 11/11, 30M auth., 4,774,568 issd. Insiders own 66.98%. 06/15, 1-for-12.174, Reverse Stock Split.